New COPD inhaler shows promise in large trial
NCT ID NCT06643078
First seen Apr 10, 2026 · Last updated May 16, 2026 · Updated 4 times
Summary
This study tested a new inhaled medicine called HL231 in 487 Chinese adults with moderate to very severe COPD. The goal was to see if HL231 works better than an existing inhaler (Ultibro) at improving lung function and reducing flare-ups over 26 to 52 weeks. Participants used the inhaler daily and had regular breathing tests.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.